Friday-Saturday, July 29-31, 2021

Activity Overview

Spasticity is a significant problem after TBI/stroke/spinal cord injury (SCI) and other UMN syndromes. Urban et. al. predicted spasticity after ischemic stroke was present in 42.6% of patients.  Adams and Hicks describe 65-78% of patients with chronic SCI has symptoms of spasticity.  Hibbard et. al. described 23.4 % of patients with traumatic brain injury have spasticity in 1998.  Education and training specialists in all the treatment options of spasticity including therapy, medications, injection with botulinum toxins, and baclofen pumps is imperative in restoration of the individual back to health, function, and potentially employment.

Onabotulinum toxin has received FDA approval for use in the lower limbs for those with predominantly lower limb symptoms such as due to spinal cord injury (SCI) and spastic diplegia from a variety of conditions such as cerebral palsy and spina bifida.  As the life span of pediatric onset conditions extends into adulthood, these conditions are no longer for just children. Physicians that treat adults must be adept at treating these conditions as well, and in fact and entire transition to adulthood clinic addresses this at Baylor.  We will review guidelines for treating adults with spasticity due to cerebral palsy and other childhood conditions.

Target Audience
Physical Medicine and Rehabilitation residents, fellows, faculty private practice physiatrists

Learning Objectives
At the conclusion of the conference, participants should be able to:

• Describe the musculoskeletal anatomy of the arm and leg as it relates to limb spasticity injection
• Describe two types of guided injections that can be used for spasticity/dystonia
• Describe suspension and injection strategies for botulinum toxin

Educational Methods
Lectures ▪ Hands-on Workshop

Evaluation
Evaluation by questionnaire will address program content, presentation, and possible bias.